Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 13/20 | 0.62 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.62 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.57 |
| ▸ | CHKA | P35790 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.46 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL27341628 | 0.84 | HRH3 (0.44) | HRH3HRH4CYP2D6CYP2C19CHKA | |
| SCHEMBL6057829 | 0.79 | EHMT2 (0.46) | HRH3HRH4CYP2D6CYP2C19ALDH1A1 | |
| Hydrochloric Acid SCHEMBL27341630 | 0.79 | PTGS2 (0.39) | HRH3HRH4 | |
| SCHEMBL13940657 | 0.79 | LSS (0.43) | HRH3CHKAALDH1A1KDM4EPOLB | |
| SCHEMBL13940606 | 0.75 | KMT2A (0.46) | HRH3CHKAALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL11201497 | 0.74 | HRH3 (0.94) | HRH3HRH4CYP2D6CYP2C19ALDH1A1 | |
| SCHEMBL13940655 | 0.74 | CHKA (0.51) | HRH3CHKAALDH1A1KDM4EPOLB | |
| SCHEMBL13940641 | 0.74 | CYP11B1 (0.42) | CHKASMN1; SMN2 | |
| SCHEMBL1690956 | 0.73 | CYP2D6 (0.85) | HRH3HRH4CYP2D6CYP2C19CHKA | |
| SCHEMBL31010302 | 0.72 | HRH3 (0.70) | HRH3HRH4CYP2D6CYP2C19CHKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1276776-B1 | CATALYST FOR PRODUCING AN ULTRA HIGH MOLECULAR WEIGHT POLYETHYLENE AND METHOD FOR PRODUCING AN ULTRA HIGH MOLECULAR WEIGHT POLYETHYLENE USING THE SAME | SAMSUNG GENERAL CHEMICALS CO (KR) | 2006-11-02 | — | — | EP | claimed |
| EP-1311499-B1 | BICYCLIC COMPOUNDS AS H3 RECEPTOR LIGANDS | ORTHO MCNEIL PHARM INC (US) | 2006-04-12 | — | — | EP | claimed |
| US-6638967-B2 | Pyrrole, furan, thiofuran and phenyl derivatives; inhibition of histamine H3 receptor activity; for example, 1-((4-(4-Pyrrolidin-1-ylmethyl-phenyl)-thien-2-yl)methyl)-pyrrolidine | ORTHO-MCNEIL PHAMRACEUTICAL, INC. | 2003-10-28 | — | — | US | claimed |
| EP-1311499-A2 | BICYCLIC COMPOUNDS AS H3 RECEPTOR LIGANDS | Ortho-McNeil Pharmaceutical, Inc. (US) | 2003-05-21 | — | — | EP | claimed |
| US-20020037896-A1 | Pyrrole, furan, thiofuran and phenyl derivatives; inhibition of histamine H3 receptor activity; for example, 1-((4-(4-Pyrrolidin-1-ylmethyl-phenyl)-thien-2-yl)methyl)-pyrrolidine | ORTHO MCNEIL PHARMACEUTICAL, INC. | 2002-03-28 | — | — | US | claimed |
| WO-2002012224-A2 | BICYCLIC COMPOUNDS AS H3 RECEPTOR LIGANDS | ORTHO MCNEIL PHARMACEUTICAL, INC. (US) | 2002-02-14 | — | — | WO | claimed |
| EP-0103100-B1 | 1-METHYL-5-NITRO-IMIDAZOLINE DERIVATIVES AND THERAPEUTIC COMPOSITIONS WHICH CONTAIN THEM AS ACTIVE PRINCIPLE | EURORESEARCH S.R.L. (IT) | 1987-10-07 | — | — | EP | claimed |
| EP-1311499-B1 | BICYCLIC COMPOUNDS AS H3 RECEPTOR LIGANDS | ORTHO MCNEIL PHARM INC (US) | 2006-04-12 | — | — | EP | disclosed |
| US-6638967-B2 | Pyrrole, furan, thiofuran and phenyl derivatives; inhibition of histamine H3 receptor activity; for example, 1-((4-(4-Pyrrolidin-1-ylmethyl-phenyl)-thien-2-yl)methyl)-pyrrolidine | ORTHO-MCNEIL PHAMRACEUTICAL, INC. | 2003-10-28 | — | — | US | disclosed |
| EP-1311499-A2 | BICYCLIC COMPOUNDS AS H3 RECEPTOR LIGANDS | Ortho-McNeil Pharmaceutical, Inc. (US) | 2003-05-21 | — | — | EP | disclosed |
| US-20020037896-A1 | Pyrrole, furan, thiofuran and phenyl derivatives; inhibition of histamine H3 receptor activity; for example, 1-((4-(4-Pyrrolidin-1-ylmethyl-phenyl)-thien-2-yl)methyl)-pyrrolidine | ORTHO MCNEIL PHARMACEUTICAL, INC. | 2002-03-28 | — | — | US | disclosed |
| WO-2002012224-A2 | BICYCLIC COMPOUNDS AS H3 RECEPTOR LIGANDS | ORTHO MCNEIL PHARMACEUTICAL, INC. (US) | 2002-02-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020037896-A1 | Pyrrole, furan, thiofuran and phenyl derivatives; inhibition of histamine H3 receptor activity; for example, 1-((4-(4-Pyrrolidin-1-ylmethyl-phenyl)-thien-2-yl)methyl)-pyrrolidine | HRH4, HRH3, HRH2 | HRH3 2/4885HRH4 1/4885CYP2D6 2890/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.